| Literature DB >> 26077956 |
Prakash Ghosh1, Md Golam Hasnain2, Debashis Ghosh3, Faria Hossain4, James Baker5, Marleen Boelaert6, Suman Rijal7, Dinesh Mondal8.
Abstract
BACKGROUND: Accurate and early diagnosis of Visceral Leishmaniasis (VL) is a prerequisite for proper treatment and restricting disease propagation in enldemic foci. An rK39 antigen-based immunochromatographic test is now recommended for its diagnostic accuracy and operational feasibility at point of care. In endemic regions of Bangladesh, rK39 or rKE16 antigen-based Rapid Diagnostic Tests (RDTs) are routinely performed on whole blood for diagnosis of VL. However, manufacturer's instructions require use of serum. Therefore, we wanted to assess whether the diagnostic accuracy of these RDTs is as good on whole blood as on serum.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26077956 PMCID: PMC4474327 DOI: 10.1186/s13071-015-0935-x
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Characteristics of Rapid Diagnostic Tests (RDTs)
| Manufacturer | Product | Format | Storage Temp. | Control line | Test line | Sample volume (μl) | Buffer volume (drops) | Min. Reading time (Minute) | Max. Reading time (Minute) |
|---|---|---|---|---|---|---|---|---|---|
| Span diagnostic Ltd. (Surat, India) | Signal®KA | Cassette | 2–8 °C | Yes | rkE16 | 20 μl of serum/blood in 80 μl of saline. 50 μl of diluted sample | Step 1:2 | 2 | 10 |
| Step 2:2 | |||||||||
| Step 3:3 | |||||||||
| Span diagnostic Ltd. (Surat, India) | Crystal®KA | Dipstick | 2–30 °C | Yes | rkE16 | Blood 20 μl | 5 | 15 | 30 |
| Serum 20 μl | |||||||||
| CTK Biotech. Inc (San Diego, USA) | On site Leishmania Ab (Rev A) rapid test | Cassette | 4–30 °C | Yes | rk39 | Blood 40 μl | 1 | 1 | 15 |
| Serum 30 μl | |||||||||
| CTK Biotech. Inc (San Diego, USA) | On site Leishmania Ab (Rev B) rapid test | Cassette | 4–30 °C | Yes | rk39 | Blood 40 μl | 1 | 1 | 15 |
| Serum 30 μl | |||||||||
| InBios international, Inc (Seattle, USA) | Kala azar Detect™ | Dipstick | 4–30 °C | Yes | rk39 | Blood 20 μl | 3 | 10 | 10 |
| Serum 20 μl |
Characteristics of the study subjects
| Characteristics | VL patients | Healthy control | Controls with TB |
|---|---|---|---|
|
|
|
| |
| Age (Years) | 18.93 ± 13.08 | 29.09 ± 8.18 | 38 ± 18.48 |
|
| 16 (53.3) | 0 (0) | 3 (11.11) |
|
| 14 (46.7) | 35 (100) | 27 (88.89) |
|
| |||
| Sex | 17 (56.7) | 31 (88.6) | 17 (56.7) |
|
| 13 (43.3) | 4 (11.4) | 13 (43.3) |
|
| |||
| Spleen size (cm)a | 5.25 ± 3.98 | - | - |
|
| |||
| Duration of fever (Weeks) | 8.53 ± 7.92 | - | - |
|
|
aSpleen size was measured through abdominal palpation and the length was measured from the coastal margin along with its axis
Product test result (absolute number)
| Product | Case (30) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresh | Stored | |||||||||||
| Blood | Serum | Blood | Serum | |||||||||
| Positive | Negative | Invalid | Positive | Negative | Invalid | Positive | Negative | Invalid | Positive | Negative | Invalid | |
|
| 30 | 00 | 00 | 30 | 00 | 00 | 30 | 00 | 00 | 30 | 00 | 00 |
|
| 30 | 00 | 00 | 29 | 01 | 00 | 30 | 00 | 00 | 30 | 00 | 00 |
|
| 30 | 00 | 00 | 30 | 00 | 00 | 30 | 00 | 00 | 30 | 00 | 00 |
|
| 30 | 00 | 00 | 30 | 00 | 00 | - | - | - | 30 | 00 | 00 |
|
| 30 | 00 | 00 | 30 | 00 | 00 | - | - | - | 30 | 00 | 00 |
| Product | Healthy Control (35) | |||||||||||
| Fresh | Stored | |||||||||||
| Blood | Serum | Blood | Serum | |||||||||
| Positive | Negative | Invalid | Positive | Negative | Invalid | Positive | Negative | Invalid | Positive | Negative | Invalid | |
|
| 00 | 35 | 00 | 00 | 35 | 00 | 00 | 35 | 00 | 01 | 34 | 00 |
|
| 00 | 34 | 01 | 00 | 35 | 00 | 01 | 34 | 00 | 00 | 35 | 00 |
|
| 00 | 35 | 00 | 00 | 35 | 00 | 00 | 35 | 00 | 00 | 35 | 00 |
|
| 01 | 34 | 00 | 02 | 33 | 00 | - | - | - | 00 | 35 | 00 |
|
| 18 | 17 | 00 | 19 | 16 | 00 | - | - | - | 00 | 35 | 00 |
| Product | Disease Control (30) | |||||||||||
| Fresh | Stored | |||||||||||
| Blood | Serum | Blood | Serum | |||||||||
| Positive | Negative | Invalid | Positive | Negative | Invalid | Positive | Negative | Invalid | Positive | Negative | Invalid | |
|
| 02 | 28 | 00 | 02 | 28 | 00 | 01 | 29 | 00 | 01 | 28 | 01 |
|
| 02 | 28 | 00 | 02 | 28 | 00 | 01 | 25 | 04 | 01 | 28 | 01 |
|
| 01 | 29 | 00 | 01 | 29 | 00 | 01 | 29 | 00 | 01 | 28 | 01 |
|
| 02 | 28 | 00 | 02 | 28 | 00 | - | - | - | 03 | 26 | 01 |
|
| 09 | 21 | 00 | 10 | 20 | 00 | - | - | - | 16 | 13 | 01 |
Specificity of different products
| Product | Fresh | Stored | ||
|---|---|---|---|---|
| Blood | Serum | Blood | Serum | |
| Specificity (Healthy Control) | ||||
| Kalazar Detect™ | 100 (96.34–100) | 100 (96.34–100) | 100 (96.34–100) | 97.14 (85.03–95.02) |
| Signal®KA | 100 (89.52–100) | 100 (89.90–100) | 100 (96.34–100) | 100 (89.90–100) |
| Crystal®KA | 100 (96.34–100) | 100 (96.34–100) | 100 (96.34–100) | 100 (89.90–100) |
| Onsite leishmania Ab (Rev A) | 97.14 (85.03–99.52) | 94.29 (80.86–99.13) | - | 100 (89.90–100) |
| Onsite leishmania Ab (Rev B) | 48.57 (31.39–66) | 45.71 (28.84–63.45) | - | 20 (8.48–36.95) |
| Specificity (Disease Control) | ||||
| Kalazar Detect™ | 93.33 (77.89–98.99) | 93.33 (77.89–98.99) | 96.67 (82.72–99.44) | 96.55 (82.17–99.42) |
| Signal®KA | 93.33 (77.89–98.99) | 93.33 (77.89–98.99) | 96.15 (80.30–99.36) | 96.55 (82.17–99.42) |
| Crystal®KA | 96.67 (82.72–99.44) | 96.67 (82.72–99.44) | 96.67 (82.72–99.44) | 96.55 (82.17–99.42) |
| Onsite leishmania Ab (Rev A) | 93.33 (77.89–98.99) | 93.33 (77.89–98.99) | - | 89.66 (72.62–97.69) |
| Onsite leishmania Ab (Rev B) | 70 (50.60–85.24) | 66.67 (47.19–82.69) | - | 44.83 (26.46–64.30) |
| Specificity (Healthy and Disease Controls combined) | ||||
| Kalazar Detect™ | 96.92 (89.30–99.54) | 96.92 (89.30–99.54) | 98.46 (91.69–99.74) | 96.88 (89.14–99.53) |
| Signal®KA | 96.88 (89.14–99.53) | 96.92 (89.30–99.54) | 98.36 (91.17–99.73) | 98.44 (91.57–99.74) |
| Crystal®KA | 98.46 (91.69–99.74) | 98.46 (91.69–99.74) | 98.46 (91.69–99.74) | 98.44 (91.57–99.74) |
| Onsite leishmania Ab (Rev A) | 95.38 (87.08–98.98) | 93.85 (84.97–98.26) | - | 95.31 (86.89–98.97) |
| Onsite leishmania Ab (Rev B) | 58.46 (45.57–70.56) | 55.38 (42.53–67.73) | - | 31.25 (24.30–57.26) |
Agreement between RDT result on blood versus serum in fresh and stored samples
| Blood vs Seruma | Agreement index (Cohen’s kappa) with 95 % CI | |
|---|---|---|
| Fresh | Stored | |
|
| 100 | 95.2 (88.39–100) |
|
| 97.6 (92.7–100) | 100 |
|
| 100 | 100 |
|
| 97.7 (93.2–100) | - |
|
| 69 (54–84) | - |
aWe didn’t perform RDT on stored blood for Rev A and Rev B following manufacturer’s instruction to avoid performing test on stored blood sample. That is why some kappa values are missing
Agreement between RDT result on Fresh versus stored in blood and serum samples
| Fresh vs Stored* | Agreement index (Cohen’s kappa) with 95 % CI | |
|---|---|---|
| Blood | Serum | |
|
| 97.6 (93–100) | 94.99 (88.12–100) |
|
| 97.6 (92.1–100) | 95.2 (88.8–100) |
|
| 100 | 100 |
|
| - | 88.4 (78.5–98.3) |
|
| - | 12.7 (0–35.6) |
*We didn’t perform RDT on stored blood for Rev A and Rev B following manufacturer’s instruction to avoid performing test on stored blood sample. That is why some kappa values are missing